Compare Amphastar Pharmaceuticals Inc (AMPH) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Gitlab Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Gitlab Inc trades at $41.63 (market cap $6.88B). The key difference: Gitlab Inc is far larger — about 8× Amphastar Pharmaceuticals Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | GTLB | |
|---|---|---|
Market Cap | $863.95M | $6.88B |
Sector | Health | Technology |
52-Week High | $30.81 | $51.04 |
52-Week Low | $16.87 | $19.42 |
Enterprise Value | $1.26B | $5.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
GitLab (GTLB) trades at $38.97, up 9.22% in 24 hours, with a bullish technical signal and recent earnings beats. The stock shows strong revenue growth, reaching $759.25M in 2025, but remains unprofitable with a negative net income margin. Analyst consensus is mixed, with 36.67% buy ratings and a $32.92 price target, while recent news highlights AI-driven product launches and leadership appointments.
Outlook: GitLab's growth trajectory and AI integration offer upside, but high valuation and persistent losses pose risks. Investors should weigh revenue momentum against profitability challenges and competitive pressures in the DevSecOps space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
